Tech Center 1600 • Art Units: 1644
This examiner grants 78% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18334531 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | Non-Final OA | Genentech, Inc. |
| 17926254 | COMPOSITIONS AND METHODS FOR PRODUCING HUMAN POLYCLONAL ANTIBODIES | Final Rejection | FLAGSHIP PIONEERING INNOVATIONS VI, LLC |
| 17275117 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY PROFILING | Final Rejection | Georgia Tech Research Corporation |
| 18317241 | ANTI-LAG3 ANTIBODIES AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18251823 | METHOD OF TREATING A TUMOR WITH A COMBINATION OF AN IL-7 PROTEIN AND A NUCLEOTIDE VACCINE | Non-Final OA | Washington University |
| 18167725 | METHODS OF ADMINISTERING CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY | Non-Final OA | Kite Pharma, Inc. |
| 18365110 | TARGETING OF PERI-NECROTIC TUMOR CELLS | Non-Final OA | Fred Hutchinson Cancer Center |
| 17639654 | Use of Calcineurin Inhibitor Free CTLA4-IG + Anti-IL6/IL6R For Long Term Immunosuppression in Solid Organ Transplant Recipients | Final Rejection | Cedars-Sinai Medical Center |
| 17727309 | ANTI-ICOS ANTIBODIES | Non-Final OA | Kymab Limited |
| 17725228 | SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD | Non-Final OA | Kymab Limited |
| 18285996 | ANTI-CD73 ANTIBODIES | Non-Final OA | CANCER RESEARCH TECHNOLOGY LIMITED |
| 18309700 | ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS | Non-Final OA | BEIGENE SWITZERLAND GMBH |
| 18278388 | PREPARATION OF SIGLEC-15 BINDING PROTEIN AND USE THEREOF | Non-Final OA | JIANGXI JEMINCARE GROUP CO., LTD. |
| 18308232 | ANTIBODIES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL | Non-Final OA | Merus N.V. |
| 17926123 | COMPOSITIONS AND METHODS FOR TREATING NONINFLAMMATORY PAIN IN SUBJECTS WITH RHEUMATOID ARTHRITIS | Non-Final OA | SANOFI BIOTECHNOLOGY |
| 18265055 | NOVEL FORMULATIONS FOR ANTIBODIES | Non-Final OA | Hexal AG |
| 17361621 | RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY | Final Rejection | Instil Bio (UK) Limited |
| 18190425 | Immunologic Treatment of Cancer | Non-Final OA | ImmunSYS, Inc. |
| 18183681 | Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof | Non-Final OA | AbelZeta, Inc. |
| 18121557 | INTESTINAL EXPRESSION OF PROGRAMMED DEATH LIGAND 1 | Non-Final OA | ENGENE, INC. |
| 18063521 | FC BINDING FRAGMENTS COMPRISING A PD-L1 ANTIGEN-BINDING SITE | Non-Final OA | F-star Therapeutics Limited |
| 18061791 | ANTI-CD277 ANTIBODIES AND USES THEREOF | Non-Final OA | UNIVERSITE DE NANTES |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy